Zyprexa Settlement With W. Virginia Shows States Can Benefit In Solo Suits
Executive Summary
Lilly's $22.5 million settlement with West Virginia to resolve litigation over its Zyprexa marketing shows the benefit for states in pursuing suits against pharmaceutical manufacturers on their own
You may also be interested in...
Lilly Wins Victory In Mississippi Zyprexa Case; Judge Says "Aggregate Proof" Of Liability Is Insufficient For Determining Fines
A federal judge has tossed out most of Mississippi's lawsuit against Lilly over Zyprexa marketing and rebuked the state for seeking excessive penalties
Lilly Wins Victory In Mississippi Zyprexa Case; Judge Says "Aggregate Proof" Of Liability Is Insufficient For Determining Fines
A federal judge has tossed out most of Mississippi's lawsuit against Lilly over Zyprexa marketing and rebuked the state for seeking excessive penalties
Should States Be Barred From Hiring Plaintiffs Firms? Pennsylvania High Court Takes Up The Question In Risperdal Suit
Janssen has won the ear of the Pennsylvania Supreme Court in its effort to get a plaintiffs firm disqualified from representing the state in Risperdal litigation